Pfizer Settles Bulk of Bextra, Celebrex Litigation for $900 Million




NEW YORK - Pfizer announced that it has reached a deal worth nearly $900 million to settle a majority of litigation filed against the company by users of its arthritis drugs Celebrex and Bextra. In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL No. 1699 (N.D. Calif.); In Re: New York Bextra/Celebrex Product Liability Litigation, No. 109535/05 (N.Y. Sup. Ct., New York Cty.).

The announcement was made Oct. 17 by Pfizer, which said the deal was spurred by two favorable court rulings regarding the paucity of scientific evidence proving that Celebrex causes heart attacks and strokes …






UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS